- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 28
The Center for Biosimilars® recaps the top stories for the week of October 28, 2019.
Transcript
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 28, 2019.
Number 5: A bipartisan bill to require patent transparency in an effort to bring down the cost of prescription drugs has been introduced in the House of Representatives.
Number 4: Drug maker Formycon has announced the start of a phase 1 clinical trial of its biosimilar referencing Stelara.
Number 3: The American Society of Clinical Oncology’s National Cancer Opinion Survey highlights the added stress that the financial burden of treatment places on patients with cancer.
Number 2: Biosimilars are beginning to gain momentum, as evidenced by strong US and global sales reported this month by some of the top biosimilar development companies.
Number 1: Pfizer has announced launch dates for 2 new anticancer biosimilars in early 2020.
Finally, last week, our e-newsletter asked whether you think that enacting legislation to create a CMS star ratings system based on biosimilar availability would help improve biosimilar uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
